The transcription regulator TOX, which has previously been reported as a marker for differential diagnosis between CTCL and benign inflammatory dermatoses (6), was found to be specifically upregulated in the malignant T cells in 4 out of 13 samples. This evidence concerns the gene TOX and primary cutaneous T-cell non-Hodgkin lymphoma.